Overview

• GSK's Arexvy is the first RSV vaccine approved for adults aged 50-59.
• The FDA's decision follows trials showing strong immune responses in this age group.
• Around 13 million Americans in their 50s are at increased risk of severe RSV due to chronic health issues.
• The CDC's advisory panel will vote on recommendations for the vaccine later this month.
• GSK is also seeking regulatory approval in Europe, Japan, and other regions.